Explore our integrated suite of active screening, analytical method establishment, cellular response assays, and end-to-end clinical research services designed for regulatory-grade worldwide dossiers.
Full qualification including HPLC, GC, LC-MS/MS, and HPTLC fingerprinting with rigorous specificity and repeatability validation.
View Technical Specs
GCP-compliant human clinical trials, bioequivalence, pharmacokinetic modeling, and dossier compilation for NDA and wellness claims.
View Technical Specs
High-content multi-cellular phenotypic assays, cytotoxicity profiling, pathway inhibition, and receptor-binding quantification.
View Technical Specs
GLP-accredited systemic toxicity, LD50, sub-acute animal models, target organ histopathology, and in vivo bio-efficacy validation.
View Technical Specs
Comparative geographical and seasonal active yield fingerprinting, optimizing biomass harvest times for elevated bio-potency.
View Technical Specs
Target-directed phenotypic screening, affinity bio-chromatography, and bioactivity-guided fractionation of complex plant phytocomplexes.
View Technical Specs
Coupled transcriptomic profiling and cellular mechanistic target deconvolution for secondary metabolites and polyphenols.
View Technical Specs
ICH Q2(R1) method validation across multi-component botanicals ensuring precise quantification of therapeutic active markers.
View Technical SpecsEvaluating molecular responses in complex primary microenvironments: Moving beyond static monolayer 2D cell cultures toward biomimetic Microphysiological Systems (MPS) and multi-organ physiological response models.
In early-stage biomedical discovery and natural product chemistry, more than 85% of lead candidates fail during phase II clinical translation due to unpredicted efficacy deficits or off-target organ toxicities. Traditional two-dimensional (2D) in vitro assays fail to emulate physiological cell-cell communication, mechanical fluid shear stresses, concentration gradients, and extracellular matrix (ECM) microenvironments. As an established ODM Cells And Organs Respond Manufacturer & Supplier, MedGence bridges this gap by engineering complex biological test beds that simulate authentic organ microarchitectures.
By capturing phenotypic, proteomic, and transcriptomic data directly from responsive cells, primary organoids, and microfluidic multi-organ chips, our platform delivers actionable quantitative data. This approach enables biopharmaceutical innovators, dietary supplement developers, and therapeutic cosmetic manufacturers to de-risk candidate pipelines early, ensuring that commercial formulations present verified physiological responses before engaging in high-capital clinical studies.
Primary cellular populations cultured in 3D hydrogels and decellularized matrices, restoring native morphological polarities and organ-specific functional responses.
Interconnected microfluidic bio-chips mimicking gut absorption, liver first-pass metabolism, and secondary target organ responses (renal, neuronal, vascular).
Integrated micro-electrodes and optical biosensors recording transepithelial electrical resistance (TEER), impedance, oxygen consumption, and cytokine kinetics.
Delivering tailored preclinical biological response intelligence for small molecule pharmaceuticals, complex herbal phytomedicines, premium functional foods, and dermatological formulations.
Deciphering multi-target mechanisms in complex botanicals. Profiling synergy across multi-component TCM herbal formulas for IND submissions.
High-predictability drug-induced liver injury (DILI), nephrotoxicity, and cardiotoxicity screening, reducing reliance on mammalian animal models.
Scientific substantiation for dietary supplement health claims: metabolic regulation, gut microbiome gut-barrier integrity, and immunomodulation.
Cruelty-free, 3D reconstructed human epidermis (RhE) and full-thickness dermal models for anti-aging, UV-photo-protection, and skin sensitization assays.
Our five-year scientific progression towards organ-on-a-chip bio-foundries, spatial transcriptomics, and automated predictive algorithms.
| Development Phase | Platform Technology | Biological Architecture | Analytical Readout | Regulatory Status |
|---|---|---|---|---|
| Phase I: Baseline (Current) | Static 3D Cell Cultures & Organoid Biobanks | Monocultures & Primary Hepatocyte/Intestinal Organoids | High-Content Confocal Imaging, ELISA, RT-qPCR, TEER | Validated (OECD / ICH) |
| Phase II: Dynamic Microfluidics (Current-2026) | Single & Dual-Organ Microfluidic Chips | Vascularized Endothelial-Epithelial Micro-Tissues | Real-time Electrochemical Sensing, Mass Spec Fingerprinting | FDA Modernization Act 2.0 |
| Phase III: Multi-Organ Systems (2026-2028) | Body-on-a-Chip Multi-Channel Bio-Foundries | Intestine-Liver-Tumor-Bone Marrow Micro-networks | Spatial Single-Cell RNA Sequencing & Toxicogenomics | Pivotal Qualification |
| Phase IV: AI Phenotypic Simulation (2028+) | Digital Twin & In Silico Hybrid Phenotyping | Bio-printed Patient-Derived Synthetic Organs | Predictive Deep-Learning Multi-Organ Pharmacokinetics | Global Harmonization R&D |
MedGence is actively executing its Next-Generation In Vitro Initiative. By merging micro-electro-mechanical systems (MEMS) with proprietary biopolymer scaffold formulations, our laboratories are reducing assay variance from the typical ±28% observed in academic literature down to <6.5% inter-batch CV in high-throughput screening environments. This technical benchmark allows commercial buyers to replace uncertain mammalian animal surrogacy with reliable, repeatable, human-relevant cellular responses.
Combining high-capacity biological testing foundries with industrial-scale extraction, precision synthesis, and finished dosage formulation facilities in Changsha, Hunan.
Fully automated 384-well liquid handling platforms executing 100,000+ biological response assays per month with minimal manual pipetting deviation.
Direct feedback between organ response data and our industrial extraction plants. Extraction, chromatography, and vacuum-drying parameters adapt in real time to preserve therapeutic potency.
Direct control from wild or GAP-certified herb farms through seasonal harvest windows, batch testing, pilot compounding, to final dosage commercial production.
Structured for Global Heads of Sourcing, Vendor Qualification Committees, and Preclinical Discovery Directors requiring institutional-grade execution.
Procurement teams working with an overseas contract research and manufacturing organization must safeguard against technical slippage, regulatory audit rejection, and proprietary formulation leakage. MedGence's operational workflow is structured around five core pillars:
Every in vitro cellular and organ response protocol includes full SOP documentation, cell line provenance, passage limits, and orthogonal validation data to allow audit-proof verification by sponsor laboratories.
Operated under enforceable international bilateral NDAs. Data isolation protocols ensure that proprietary botanical fractions and customer target profiles are sequestered within dedicated server silos.
Raw materials, concentrated extracts, and finished dosage forms undergo chemical fingerprinting, residual solvent tests, heavy metal screening, microbiological assay, and bio-response activity testing.
Navigating complex international regulatory pathways with data compliant with the 3Rs principles and modern non-animal testing directives.
Fully adapted to the US FDA's landmark shift permitting cell-based assays, microphysiological systems (MPS), and bioprinted tissues to substitute animal toxicology for IND submissions.
Strict implementation of Replacement, Reduction, and Refinement (3Rs) protocols adhering to OECD Test Guidelines for in vitro toxicity, skin corrosion, and ocular irritation.
All electronic assay records, spectrophotometer logs, and confocal image stacks are securely managed with complete audit trails and role-based access protocols.
In-depth technical answers addressing assay validity, manufacturing scalability, client intellectual property, and global regulatory submission readiness.
Select our validated research packages and CDMO services to accelerate your product pipeline from initial screening to commercial batch delivery.
Comprehensive chromatographic method development, impurity profiling, and ICH validation for global pharmacopoeia compliance.
View Technical Specs
End-to-end clinical execution, institutional review board coordination, human safety profiling, and clinical endpoint substantiation.
View Technical Specs
Cell viability, molecular apoptosis tracking, anti-inflammatory cytokine assays, and direct target-engagement bio-evaluations.
View Technical Specs
In vivo proof-of-concept, metabolic pathway mapping, sub-chronic toxicity, and safe maximum tolerated dose (MTD) determinations.
View Technical Specs
Systematic multi-origin geo-climatic active ingredient mapping to lock in prime botanical biomass for manufacturing runs.
View Technical Specs
Target identification, natural library screening, and chromatographic isolation of novel lead molecules for pharmaceutical development.
View Technical Specs
Target active-density screening across distinct harvest seasons, establishing verifiable incoming raw material quality benchmarks.
View Technical Specs
High-predictability organ-level screening for drug discovery, consumer safety substantiation, and functional claim registration.
View Technical Specs